Haemonetics Corporation (NYSE:HAE) reported Q1 2018 earnings this Morning, coming in at $0.33 per share, beating Wall Street’s estimates of $0.31 per Share. Revenue for the quarter came in at $211.00 million missing the streets estimates of $211.29 million
Analyst Coverage For Haemonetics Corporation (NYSE:HAE)
These are 1 Sell Rating, 5 Hold Ratings, 2 Buy Ratings .
The current consensus rating for Haemonetics Corporation (NYSE:HAE) is Hold (Score: 2.13) with a consensus target price of $38.71 , a potential (6.01% downside)Recent Insider Trading for Haemonetics Corporation (NYSE:HAE)
- On 5/22/2017 Ronald Merriman, Director, sold 17,471 with an average share price of $40.33 per share and the total transaction amounting to $704,605.43.
- On 12/12/2016 Ronald G Gelbman, Director, sold 5,683 with an average share price of $40.30 per share and the total transaction amounting to $229,024.90.
- On 8/17/2016 Ronald Merriman, Director, sold 4,337 with an average share price of $35.14 per share and the total transaction amounting to $152,402.18.
- On 8/4/2016 Christopher Simon, CEO, bought 60,000 with an average share price of $35.00 per share and the total transaction amounting to $2,100,000.00.
- On 10/26/2015 Byron Selman, Insider, sold 344 with an average share price of $32.13 per share and the total transaction amounting to $11,052.72.
- On 10/26/2015 Christopher J Lindop, CFO, sold 436 with an average share price of $32.13 per share and the total transaction amounting to $14,008.68.
Recent Trading for Haemonetics Corporation (NYSE:HAE) Shares of Haemonetics Corporation closed the previous trading session at 42.30 up +1.11 2.69% with 245,704 shares trading hands.